Results 241 to 250 of about 1,300,736 (395)

Antitumor efficacy of intermittent low‐dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche

International Journal of Cancer, EarlyView.
What's New? Novel immunomodulatory insights derived from experimental models and clinical samples reveal the cancer‐preventive potential of intermittent low‐dose erlotinib plus sulindac (ERL + SUL). This study shows that ERL + SUL treatment upregulates MHC class I and II expression and remodels the immune cell niche, with significant tumor suppression ...
Chakrapani Tripathi, Jorge E. Tovar Perez, Sabeeta Kapoor, Ahmed Muhsin, Wan Mohaiza Dashwood, Yunus Demirhan, Melek Demirhan, Alessandro Shapiro, Altaf Mohammed, Shizuko Sei, Jacklyn Thompson, Mahira Zaheer, Krishna M. Sinha, Powel H. Brown, Michelle I. Savage, Eduardo Vilar, Praveen Rajendran, Roderick H. Dashwood   +17 more
wiley   +1 more source

Association between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 with alloimmunization in transfusion-dependent patients with thalassemia: the first case-control study in Iran. [PDF]

Ann Hematol
Kargar M, Kaydani GA, Keikhaei B, Saki N, Jalalifar MA.   +4 more
europepmc   +1 more source

HLA ANTIGEN EXPRESSION IN MYOSITIS

The Lancet, 1985
Isenberg, D, Rowe, D, Beverley, P
openaire   +4 more sources

Expression and immmunogenicity of HLA-B27 in high-transfection recipient P815: [PDF]

, 1989
Kuon, W., Riethmüller, Gert, Thureau, S. R., Weiss, Elisabeth H., Wildner, G.   +4 more
core   +1 more source

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

International Journal of Cancer, EarlyView.
What's New? Tumor necrosis factor (TNF) can promote tumor resistance to immune checkpoint inhibitors (ICIs), which are now the standard treatment for advanced melanoma patients. Here, in an advanced melanoma patient cohort, TNF was investigated for a possible predictive relationship with ICI response. Assessments show that after 12 weeks of ICI therapy,
Mathieu Virazels, Amélie Lusque, Stéphanie Brayer, Matthieu Genais, Carine Dufau, Jean Milhès, Thomas Filleron, Cécile Pagès, Vincent Sibaud, Laurent Mortier, Olivier Dereure, Maha Ayyoub, Amandine Fabre, Nathalie Andrieu‐Abadie, Vera Pancaldi, Céline Colacios, Nicolas Meyer, Bruno Ségui, Anne Montfort   +18 more
wiley   +1 more source

Vaccine-induced donor-specific HLA antibodies: a case report highlighting sensitization risks in renal transplant waitlisted patients. [PDF]

Front Immunol
Kakodkar P, Shekari N, Mainra R, Webster D, Pearce T, Wu F, Mostafa A.   +6 more
europepmc   +1 more source

Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. [PDF]

, 1988
Andrea Anichini, Chiara Castelli, Gabriella Sozzi, G Fossati, Giorgio Parmiani   +4 more
openalex   +1 more source

Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives

Interdisciplinary Medicine, EarlyView.
Infographics of this review introducing the current treatment strategies, types of nanomaterials, and their advantages in AML treatment (Created with BioRender.com, a license purchased, accessed on March 26, 2024). Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by poor prognosis, high relapse rates ...
Jiarui Zhao, Jiaqi Cui, Lixuan Wang, Xinyi Shi, Jiayan Ding, Muhammad Farhan Sohail, Irshad Hussain, Qihui Liu, Fangfang Chen   +8 more
wiley   +1 more source

Identification of a novel biomarker of antibody-mediated rejection in heart transplantation: synergistic effect of anti-nuclear antibodies and <i>de novo</i> donor-specific IgG HLA antibodies. [PDF]

Front Immunol
Misra MK, McMullen P, Kim GH, Marino SG.
europepmc   +1 more source

Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice. [PDF]

, 1989
Femia Kievits, Josien F.A.M. Wijffels, W. Lokhorst, P. Iványi   +3 more
openalex   +1 more source